Latham Guides Israeli Biopharma Targeting $50M In US IPO
Israeli biopharmaceutical company Ayala Pharmaceuticals said Monday it hopes to raise $50 million in a U.S. initial public offering steered by Latham & Watkins LLP, with the proceeds going toward developing...To view the full article, register now.
Already a subscriber? Click here to view full article